JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 25, 2026, 10:56PMOS Can Affect Much More Than Periods or Fertility – PCOS Awareness Association
-
Jul 25, 2026, 10:42Asma Khalil: Recreational Drug Use During Pregnancy, What Every Expectant Mother Should Know!
-
Jul 25, 2026, 10:40Khalil Faaed: Are Complex Y Chromosome Rearrangements the Missing Link in Unexplained Male Infertility?
-
Jul 25, 2026, 10:38Sean Lauber: Does Transferring a Cleavage or Blastocyst Stage Embryo Affect the Chance of Having a Boy?
-
Jul 25, 2026, 10:33Rokaya Hachicho: The Hidden Cost of Excessive Laser Use During Trophectoderm Biopsy!
-
Jul 25, 2026, 10:31Join the ISUOG Webinar on Late-Evolving Fetal Anomalies – ISUOG
-
Jul 25, 2026, 10:29Waiting Before Clamping the Umbilical Cord Improves Neonatal Outcomes! – RCOG
-
Jul 25, 2026, 10:27Christopher Robinson: The Impact of Body Mass Index on Misoprostol Dosing for Labor Induction!
-
Jul 25, 2026, 10:26Heavy Menstrual Bleeding and Dysmenorrhea in Adolescents – IJGO